På denne side bringer DANSK BIOTEK nyheder fra medlemmerne, som på denne måde får mulighed for at blive ekstra eksponeret.

Vi modtager derfor gerne pressemeddelelser og andre nyheder. Send dem til Dorte Dannemann, hjælp af denne formular.

11 Mar 2016

Biotek Salon #8: Evolving strategies in Immuno-Oncolcogy and Cancer Vaccines

April 14th, from 3PM thru 5PM
At COBIS (Ole Maaløes Vej 3, 2200 N Copenhagen)

Bioanalytical information about the mutational landscape and activation of signalling cascades of tumor cells has sparked the development of targeted agents. Novel and powerful immuno-therapeutic concepts have recently been developed. These developments have opened new avenues for personalization of therapy for cancer patients. Personalized therapy has the vision and concept to increase the cancer therapy efficacy and decrease the potential adverse events.

Personalized medicine requires specific concepts for clinical development as defining patient eligibility based on biomarkers/molecular markers rather than tumor type, exploring combinatorial therapies and adpative designs.

The interactive seminar is planned to outline the most promising diagnostic tools to guide patient selection. Clinical study designs that are specifically tailored to personalized therapy are presented and discussed. Critical aspects of approach and conduct of clinical studies for immunotherapy in cancer patients will be presented including integration of immune-related response criteria, early response assessments and immunomonitoring in the conduct of clinical studies.

inVentiv attendees:
-Esther Mahillo PhD, MBA
-Richard Davis, Director Business Development
-Thomas Moehler MD PhD, Vice President, Medical&Scientific Affairs Hematology/Oncology

Agenda for presentation:
• Background of immune oncology and targeted agents
• integration of diagnostic strategies to evaluate cancer mutations and immune status
• Development of personalized therapies with oncology vaccines
• detection of early signs of efficacy and anti-tumor response in various oncology indications
• Phase I and first-in-man in immuno-oncology and study designs for personalized therapy
• Immune related AE management and immune related response detection
• Future perspectives

If you can't find it here or have feedback to our website, please do not hesitate to contact dd@danskbiotek.dk or 28895854

Copyright 2016 Danskbiotek. All rights reserved.